כניסה 
עקבו אחרינו בפייסבוק אקטיליז - Actilyse
מתוך ויקירפואה
| אקטיליז - Actilyse | ||
|---|---|---|
| מרכיב פעיל | RECOMBINANT HUMAN TPA | |
| קבוצה פרמקולוגית (ATC) | "ENZYMES" | |
| שם התרופה | "אקטיליז®" (קישור לדף התרופה במאגר משרד הבריאות) |
|
| סל הבריאות | לא כלול | |
התוויות |
Acute Myocardial infarction: Actilyse is indicated for use in the management of acute myocardial infarction (AMI) in adults for the lysis of thrombi obstructing coronary arteries, the reduction of infarct size, the improvement of ventricular function, the reduction of the incidence of congestive heart failure and the reduction of mortality associated with AMI. Treatment should be initiated as soon as possible after the onset of AMI symptoms. Massive pulmonary embolism with hemodynamic deprivation : Actilyse is indicated in the management of acute massive pulmonary embolism (PE) in adults : for the lysis of acute pulmonary emboli, defined as obstruction of blood flow to a lobe or multiple segments of the lung, and for the lysis of pulmonary emboli accompanied by unstable hemodynamics e.g. failure to maintain blood pressure without supportive measures. The diagnosis should be confirmed by objective means, such as pulmonary angiography or noninvasive procedures such as lung scanning. For fibrinolytic treatment of acute ischaemic stroke, restricted to prescription by specialist in neurology : Treatment must be started within 3 hours of onset of the stroke symptoms and after prior exclusion of intracranial haemorrhage by means of appropriate imaging techniques
| |
| שם יצרן | BOEHRINGER INGELHEIM PHARMA GmbH & CO.KG | |
| שם בעל הרישום | SALOMON,LEVIN & ELSTEIN LTD | |
| עלון לרופא | "עלון לרופא באנגלית" | |